BiotechTube

Alemtuzumab (Campath-1H)

Phase 1/2Completed
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Peripheral T-cell Lymphomas

Conditions

Peripheral T-cell Lymphomas

Trial Timeline

Sep 1, 2006 → May 1, 2015

NCT ID
NCT00453427

About Alemtuzumab (Campath-1H)

Alemtuzumab (Campath-1H) is a phase 1/2 stage product being developed by Sanofi for Peripheral T-cell Lymphomas. The current trial status is completed. This product is registered under clinical trial identifier NCT00453427. Target conditions include Peripheral T-cell Lymphomas.

What happened to similar drugs?

20 of 20 similar drugs in Peripheral T-cell Lymphomas were approved

Approved (20) Terminated (4) Active (0)
✅Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mgYuhanApproved
✅Anplag Tab. 100mg bid + Anplag Tab. 100mg tidYuhanApproved
✅QUTENZA + Lidocaine + TramadolAstellas PharmaApproved
✅Qutenza + PregabalinAstellas PharmaApproved
✅Duloxetine + Pregabalin + PlaceboShionogiApproved
✅Mecobalamin IV Injection + Mecobalamin IM injection + Mecobalamin IV or IM injectionEisaiApproved
✅Ticagrelor + clopidogrelAstraZenecaApproved

Hype Score Breakdown

Clinical
9
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00453427Phase 1/2Completed

Competing Products

20 competing products in Peripheral T-cell Lymphomas

See all competitors
ProductCompanyStageHype Score
SON-080Sonnet BioTherapeuticsPhase 1/2
18
LY3857210 + PlaceboEli LillyPhase 2
35
Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mgYuhanApproved
43
YHD1119 + LyricaYuhanPhase 1
29
Anplag Tab. 100mg bid + Anplag Tab. 100mg tidYuhanApproved
43
YHD1119 + LyricaYuhanPhase 1
29
YHD1119 + LyricaYuhanPhase 3
40
YHD1119 300mg + YHD1119 300mgYuhanPhase 1
29
DS-5565 tablet + pregabalin capsule + Placebo tablet + placebo capsuleDaiichi SankyoPhase 2
35
edoxaban + Clopidogrel + AspirinDaiichi SankyoPhase 2
35
DS-5565 + placeboDaiichi SankyoPhase 3
40
Mirogabalin + PlaceboDaiichi SankyoPhase 3
40
DS-5565Daiichi SankyoPhase 3
40
Valemetostat TosylateDaiichi SankyoPhase 2
39
ASP3662 + pregabalin + ASP3662 placebo + pregabalin placeboAstellas PharmaPhase 2
27
QutenzaAstellas PharmaPre-clinical
26
QUTENZA + Lidocaine + TramadolAstellas PharmaApproved
43
Qutenza exposureAstellas PharmaPre-clinical
26
QUTENZAAstellas PharmaPhase 3
40
Qutenza + PregabalinAstellas PharmaApproved
43